drugset
drugset / Trial / NCT06385509

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

NCT06385509 ↗

Phase 4 Active not recruiting 110 enrolled Tolmar Inc. ICON plc · collab
NaSingle-groupOpen-labelTreatment

Summary

TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.

Timeline

Start
2024-05-10
Primary completion
2025-11
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Undecanoate Small molecule 237 mg —

Indications

hypogonadism, male